<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6546">
  <stage>Registered</stage>
  <submitdate>27/01/2017</submitdate>
  <approvaldate>27/01/2017</approvaldate>
  <nctid>NCT03036852</nctid>
  <trial_identification>
    <studytitle>Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease</studytitle>
    <scientifictitle>A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease</scientifictitle>
    <utrn />
    <trialacronym>SOF/VEL ESRD</trialacronym>
    <secondaryid>2016-003625-42</secondaryid>
    <secondaryid>GS-US-342-4062</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis c</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SOF/VEL

Experimental: SOF/VEL - SOF/VEL for 12 weeks


Treatment: drugs: SOF/VEL
400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) - SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.</outcome>
      <timepoint>Posttreatment Week 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of Participants Who Permanently Discontinued the Study Drug Due to an Adverse Event</outcome>
      <timepoint>Up to Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4) - SVR4 is defined as HCV RNA &lt; LLOQ 4 weeks after the last dose of study drug.</outcome>
      <timepoint>Posttreatment Week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24) - SVR24 is defined as HCV RNA &lt; LLOQ 24 weeks after the last dose of study drug.</outcome>
      <timepoint>Posttreatment Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome>
      <timepoint>Up to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in HCV RNA</outcome>
      <timepoint>Up to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants With Virologic Failure - Virologic failure is defined as:
On-treatment virologic failure:
Breakthrough (confirmed HCV RNA = LLOQ after having previously had HCV RNA &lt; LLOQ while -on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
Non-response (HCV RNA persistently = LLOQ through 8 weeks of treatment)
Virologic relapse:
Confirmed HCV RNA = LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at last on-treatment visit.</outcome>
      <timepoint>Up to Posttreatment Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants Who Develop Resistance to SOF and VEL During Treatment</outcome>
      <timepoint>Up to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants Who Develop Resistance to SOF and VEL After Discontinuation of Therapy</outcome>
      <timepoint>Up to Posttreatment Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic (PK) Parameter: AUCtau of SOF and its metabolites - AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval)</outcome>
      <timepoint>Predose and up to 12 hours Postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic (PK) Parameter: AUCtau of VEL - AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval)</outcome>
      <timepoint>Predose and up to 12 hours Postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic (PK) Parameter: Tmax of SOF and its metabolites - Tmax is defined as the time of Cmax (the maximum concentration of drug)</outcome>
      <timepoint>Predose and up to 12 hours Postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic (PK) Parameter: Tmax of VEL - Tmax is defined as the time of Cmax (the maximum concentration of drug)</outcome>
      <timepoint>Predose and up to 12 hours Postdose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Chronic HCV infected, male and non-pregnant/non-lactating females aged 18 years or
             older who are on dialysis for ESRD, including adults with HIV co-infection if they are
             suppressed on a stable, protocol-approved antiretroviral (ARV) regimen for =8 weeks
             prior to screening.

        NOTE: Other protocol defined Inclusion/</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>22/03/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Monash Medical Centre - Clayton</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>0128 - Box Hill</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alcorc√≥n</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Majadahonda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hampstead</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Portsmouth</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objectives of this study are to evaluate safety, efficacy and tolerability of
      treatment with sofosbuvir (Sovaldi¬Æ)/velpatasvir (Epclusa¬Æ; SOF/VEL) for 12 weeks in adults
      with chronic hepatitis C virus (HCV) infection who are on dialysis for End Stage Renal
      Disease (ESRD).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03036852</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Gilead Study Team</name>
      <address />
      <phone>1-833-GILEAD-0(1-833-445-3230)</phone>
      <fax />
      <email>GS-US-342-4062@gilead.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>